CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel, J.D., Ph.D, Executive Vice President and Chief Business Officer, is leaving the Company to become Chief Executive Officer of a venture-backed startup biotechnology company. Dr. Quisel’s departure from Acceleron is effective as of February 24.
“John has been a valued colleague and trusted leader at Acceleron, contributing meaningfully to the Company’s growth and success,” said Habib Dable, President and Chief Executive Officer of Acceleron. “During his nearly 14 years here, John has lent his scientific, business, and legal acumen to many important corporate initiatives. I’ve personally enjoyed working alongside him and am delighted for him to take this next natural step in his career.”
Dr. Quisel joined Acceleron in 2006 and has held a variety of roles spanning legal, intellectual property, business development and corporate strategy. During his time with the organization, he supported venture capital financings, the company’s 2013 initial public offering, subsequent public offerings, and a range of collaboration and licensing agreements, including Acceleron’s longstanding development and commercialization agreements with Celgene Corp., now Bristol-Myers Squibb.
“I’m enormously grateful for my time at Acceleron and proud of all that we accomplished throughout the years,” said Dr. Quisel. “Although my decision to depart was a difficult one, the opportunity to lead another organization on what I believe will be a similarly successful path was too enticing to ignore. I leave Acceleron with cherished memories and the knowledge that the Company is on the right track, steered by a talented leadership team.”
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.